Awards
This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page | Contact Us | Sign In | Register
David Miller Award Recipients

David Miller Award Program

Individuals Supported through the Program

 

The following individuals have received travel support to attend various meetings through the mechanisms established through the David Miller Awards program. Speakers represent various sectors and viewpoints that enhance each session and help drive the various discussions. For further details on each meeting's scientific program, please follow the link for the corresponding program in each title.

2020 Winter Meeting Program

A Chemical Category-Based Approach for Selecting and Screening PFAS for Toxicity and Toxicokinetic Testing
Grace Patlewicz, US EPA/CCTE

Use of High-Throughput Toxicity Testing to Assess PFAS
Michael DeVito, US EPA/CCTE

Application of High-Throughput Toxicokinetics in the Assessment of PFAS
Barbara Wetmore, US EPA/CCTE

Incorporating Varying Levels of Data into Carcinogenicity Assessments in FEMA GRAS Expert Panel Determinations
Samuel Cohen, University of Nebraska Medical Center

Making the Case for In Vitro and In Silico Data for Assessing Carcinogenic Potential Substances: Challenges and Understanding the Data
Maureen Gwinn, US EPA/CCTE

Overview of the US EPA Computational Toxicology Dashboard and ToxCast/Tox21 Screening Program Data: Tools for Users
Katie Paul-Friedman, US EPA/CCTE

A Regulatory Perspective on Application of High-Throughput Screening (HTS) Data in Risk Assessment: Derivation of Toxicity Values Using HTS Data
Jason Lambert, US EPA/NCEA

In Vitro New Approach Methodologies following Prioritization Using High-Throughput Screening Data—Challenges, Validation, and Uses of Tissue Chip Technology
Courtney Sakolish, Texas A&M University

New Data Requirements for Sunscreen Over the Counter Actives—Challenges and Opportunities
Sarah Vater, ToxStrategies, Inc.

Whither the Safe Dose for Perfluorooctanoate (PFOA)?
Michael Dourson, Toxicology Excellence for Risk Assessment

From Lab Bench to Clinic Bedside: Investigating Inhalation Toxicity of E-cigarettes
Maciej Goniewicz, Roswell Park Comprehensive Cancer Center

 

 

2019 Summer Meeting Program

The Myriad Interactions of Drugs with Gut Bacterial Beta-Glucuronidases
Sam Pellock, University of North Carolina at Chapel Hill

Communicating and Translating the US EPA’s Science to Diverse Stakeholder Groups from the Scientific Community to the General Public
Monica Linnenbrink, US EPA/NCCT 

Chemical Hazards on Military Bases: Communicating Laboratory Science to Potentially Exposed Military Personnel
Sarah Blossom, Arkansas Children's Research Institute

Mode-of-Action for Inorganic Arsenic-Induced Cancer and Evaluation of Animal Studies
Samuel Cohen, University of Nebraska Medical Center

Implications of the Threshold Approach for Environmental Risk Assessment for Inorganic Arsenic in the Drinking Water
Sabine Lange, Texas Commission on Environmental Quality

Thyroid Hormone Triggers: Why DTT and Not DNT?
Mary Gilbert, US EPA/NHEERL

Per- and Poly-fluoroalkyl Substances (PFAS): A Lifecycle Perspective
Jamie DeWitt, East Carolina University, Brody School of Medicine

The Key Characteristics of Carcinogens Concept Is Now Incorporated into the International Agency for Cancer Research’s (IARC) Preamble: Implications
Jay Goodman, Michigan State University

Dietary Exposures: Role of the Microbiome in Influencing the Effect of Environmental Compounds on Gut Health
Clint Allred, Texas A&M University

Observations and Challenges in Deciphering Study to Study Results of Microbiome Analysis in Toxicological Risk Assessment of Xenobiotic Residues in Food
Carl Cerniglia, US FDA/NCTR

Implementation of Nonanimal Approaches for Acute Systemic Toxicity
Grace Patlewicz, US EPA/NCCT

 

 

Determining Relevant Low-Level Chemical Exposures for Safety Assessments of Consumer Products

Hazardous Substances in Articles—Who Is Expected to Demonstrate Safe Use and How Can It Be Done
Andreas Ahrens, European Chemicals Agency (ECHA)

Canada’s Chemicals Management Plan—The Role of Consumer Product Exposures over the Last Decade
Angelika Zidek, Health Canada

Fusing Exposure Data and Models to Reduce Uncertainty
John Wambaugh, US EPA/NCCT

Fully Quantitative, Mass-Balance-Based Framework to Consistently Quantify High-Throughput Exposure and Human Toxicity Effects for ~10,000 Chemicals Found in Consumer Product Applications
Peter Fantke, Technical University of Denmark

New Exposure Databases from the US EPA: Harmonized Chemical, Product, and Monitoring Information
Kristin Issacs, US EPA/NERL

Evidence Based and Risk Informed Policy Making in Europe post Brexit—Possible Directions
Ragnar Löfstedt, King's College, London 

Why Your Data Doesn’t Matter
David Zaruk, Odisee University College Brussels

2019 Winter Meeting Program

Risk Assessment Communications—Perspectives from Different Sectors
Elisabeth Anderson, Michigan State University

Evaluating Real and Potential Risks of Allergy or Celiac Disease from Genetically Engineered Crops
Rick Goodman, University of Nebraska

A European Regulatory Perspective on the Qualification of Non-Genotoxic Impurities in Drug Substance/Drug Products
Leon van Aerts, Medicines Evaluation Board

 

Considerations on Quantification of Uncertainty in Mixtures Studies
Claudio Fuentes, Oregon State University

Review of the Evidence for Thresholds for DNA-Reactive and Epigenetic Experimental Chemical Carcinogens
Gary Williams and Tetyana Kobets, New York Medical College

Modeling:  Issues and Controversies from a Biologist’s Perspective
Lynne Haber, University of Cincinnati

Cannabis in our Food Supply: The Importance of Updating and Implementing the Supply Chain, Manufacturing Practices and Specifications, and Regulatory Oversight
Roger Clemens, University of Southern California


2018 Summer Meeting Program

 

In Silico Modeling of Liver Toxicity—Where Are We Now?
Mark Hewitt, Wolverhampton University

Adverse Outcome Pathways As Tools to Predict Liver Toxicity in In Vitro Models
Mathieu Vinken, Vrije Universiteit Brussels

Hexabromocyclododecane (HBCD): A Case Study Applying Tiered Testing for Human Health Risk Assessment
Carole Yauk, Health Canada

Examination of the Acute Oral versus Acute Dietary Testing in Avian Risk Assessment Conclusions
Gina Hilton, PETA International Science Consortium

The Adverse Outcome Pathway: A Framework Supporting 21st Century Toxicology
Gary Ankley, US EPA-ORD

Defining Points-of-Departure from New Approach Methods
Katie Paul Friedman, US EPA-NCCT

Adversity in the Light of REACH
Helmut Greim, Technical University of Munich

A Perspective from Industry—Adverse Effects As the Basis for Regulatory Decisions: What Is Adverse?
Rebecca Clewell, ToxStrategies, Inc.

A View on Adverse Effects and Decision Making at US FDA-CFSAN
Antonia Mattia, US FDA-CFSAN

Bioaccumulation of PFASs in Terrestrial Species and Marine Mammals: Canadian Regulatory Perspective
Jessy Kurias, Environment and Climate Change Canada

Relevance of Wildlife Bioaccumulation Data to Human Health Protection
Susanne Brander, Oregon State University


2018 Winter Meeting Program

 

Using Computational Data and High-Throughput Testing (ToxCast Data) in Support of the KCC
Weihsueh Chiu, Texas A&M University

Case Studies for Integrating Data Collected to Build MOA/AOP and Identify Data Gaps
Nikolai Chepelev, Health Canada

Grouping of UVCBs Using Chemical-Biological Read-Across: Case Study of Petroleum Substances
Ivan Rusyn, Texas A&M University

Research Challenges Associated with PFASs: Ubiquitous Multisystem Toxicants
Jamie Dewitt, East Carolina University

High-Throughput Modeling of Near- and Far-Field Exposure to Chemicals in Consumer Products
Olivier Jolliet, University of Michigan

Evaluation of Therapeutics for the Treatment of Severely-Debilitating or Life-Threatening Diseases
Jennifer Goldman, Rush University